Diabetes Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Diabetes Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
American Association of Clinical Endocrinologists
AACE Response to Insulin Glargine Cancer Risk Articles in Diabetologia
July 13th, 2009
On June 26, 2009 several articles published online in Diabetologia by the European Association for the Study of Diabetes investigated the possible relationship between use of insulin glargine (Lantus, sanofi-aventis) and the development of certain malignancies. The authors themselves, and the accompanying editorial, cautioned against over-interpretation of their limited data and analyses, which precluded them from drawing any firm conclusions. For example, there were contradictory findings among the studies, patient populations were not always comparable, and the duration of observation was short. Nonetheless, since the relationship of type 2 diabetes to cancer is of critical importance,...
Source: Diabetes Week (2009-07-13)
|
